Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of OPN-305 for prevention of delayed graft dysfunction after high-risk kidney transplantation
2012-001455-39Phase 2Completed
- Sponsor
- Opsona Therapeutics
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Kidney Graft Dysfunction (DGF) and delayed graft function (DGF) comparing OPN-305 with Placebo (2 arms). Primary endpoint: TLR2 receptor occupancy. Started Jul 2012; status: completed.
02
Drugs
tomaralimab
03
Conditions
Kidney Graft Dysfunction (DGF)delayed graft function (DGF)
Beyond the preview
Go deeper on 2012-001455-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001455-39.